KOELIS
Corentin Bellee is an experienced regulatory affairs professional currently serving as the Regulatory Affairs Manager at KOELIS since July 2021. Prior to this role, Corentin worked as a Regulatory Affairs Specialist at Zimmer Biomet from July 2017 to July 2021, where responsibilities included leading regulatory actions for the implementation of Medical Device Regulations and overseeing external resources in CE marking for various classes of orthopedic medical devices. Earlier experience includes serving as Regulatory Affairs Project Manager at AMPLITUDE, focusing on CE marking for orthopedic devices and participating in product development, and as a Junior Project Manager at LISI Medical, involved in the development of cemented femoral stems. Corentin holds an Engineer's degree in Biological Engineering from Université de Technologie de Compiègne and a DUT in Physical Measurements from IUT de Caen, along with a Baccalauréat in Scientific studies from Lycée Jean Rostand Caen.
KOELIS
KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.